{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:41:30Z","timestamp":1759693290760,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006588","name":"Ministarstvo Znanosti, Obrazovanja i Sporta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.mehy.2012.09.010","type":"journal-article","created":{"date-parts":[[2012,10,10]],"date-time":"2012-10-10T13:54:21Z","timestamp":1349877261000},"page":"869-871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Can estrogen receptor overexpression in normal tissues due to previous estrogen deprivation explain the fulvestrant efficacy in breast cancer therapy?"],"prefix":"10.1016","volume":"79","author":[{"given":"Sven","family":"Kurbel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2012.09.010_b0005","first-page":"6739","article-title":"Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer","volume":"61","author":"Robertson","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.mehy.2012.09.010_b0010","unstructured":"European Medicines Agency. Assessment report for Faslodex (fulvestrant). Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000540\/WC500098922.pdf. (Accessed 01.09.2012)."},{"key":"10.1016\/j.mehy.2012.09.010_b0015","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.mehy.2012.09.010_b0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1677\/erc.1.00991","article-title":"Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer","volume":"12","author":"Nicholson","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.mehy.2012.09.010_b0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1677\/erc.1.01273","article-title":"Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor\/growth factor signaling crosstalk","volume":"13","author":"Massarweh","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.mehy.2012.09.010_b0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jsbmb.2005.04.025","article-title":"Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment","volume":"95","author":"Santen","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.mehy.2012.09.010_b0035","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/1097-0142(19930215)71:4<1266::AID-CNCR2820710416>3.0.CO;2-K","article-title":"Up-regulation of estrogen receptor by tamoxifen in human breast cancer","volume":"71","author":"Noguchi","year":"1993","journal-title":"Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.mehy.2012.09.010_b0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0959-8049(00)00222-7","article-title":"Does tamoxifen change oestrogen and progesterone receptor expression in the endometrium and breast?","volume":"36","author":"Karck","year":"2000","journal-title":"Eur J Cancer"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987712004239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987712004239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:13:08Z","timestamp":1759691588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987712004239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0306987712004239"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2012.09.010","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can estrogen receptor overexpression in normal tissues due to previous estrogen deprivation explain the fulvestrant efficacy in breast cancer therapy?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2012.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}